Background: The herpes simplex virus (HSV) infection is initiated by VP16, a viral transcription factor that activates the viral immediate-early (IE) genes. VP16 recognizes the IE gene promoters by forming a multiprotein complex with Oct-1 and HCF1 (host cell factor 1), a nuclear protein required for progression through the G1 phase of the cell cycle. This multiprotein complex, called C1, is responsible for transcription of the HSV immediate-early genes and may be critical for the regulation of the HSV lytic-latent cycle. A second HCF-like protein, designated HCF2 is smaller than HCF1 and is homologous with HCF1 in the beta-propeller domain, which is required for association with VP16. HCF2 associates with VP16 and supports complex assembly with Oct-1 and DNA, although binds VP16 less efficiently than HCF1. This VP16 binding selectivity is dictated by differences in the kelch repeats of the beta-propeller domains of HCF1 and HCF2.

Description: Rabbit polyclonal to Host cell factor 2

Immunogen: KLH conjugated synthetic peptide derived from Host cell factor 2

Specificity:  ·Reacts with Human, Mouse and Rat.

·Isotype: IgG

Application:  ·Western blotting: 1/100-500. Predicted Mol wt: 86 kDa;

·Immunohistochemistry (Paraffin/frozen tissue section): 1/50-200;

·Immunocytochemistry/Immunofluorescence: 1/100;

·Immunoprecipitation: 1/50;

·ELISA: 1/500;

·Optimal working dilutions must be determined by the end user.